HC Wainwright Reaffirms “Buy” Rating for Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. (NASDAQ:MCRB)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Friday, MarketBeat reports. They currently have a $19.00 price target on the biotechnology company’s stock, up from their prior price target of $15.00. HC Wainwright’s target price would suggest a potential upside of 40.12% from the company’s current price.
MCRB has been the subject of several other research reports. Canaccord Genuity set a $20.00 price target on shares of Seres Therapeutics and gave the company a “buy” rating in a report on Thursday, May 4th. Cantor Fitzgerald set a $16.00 price target on shares of Seres Therapeutics and gave the company a “buy” rating in a report on Thursday, May 4th. ValuEngine upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. BidaskClub upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Zacks Investment Research upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a report on Friday, July 14th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $16.17.
Seres Therapeutics (NASDAQ MCRB) opened at 13.56 on Friday. The stock has a 50 day moving average price of $12.20 and a 200-day moving average price of $10.57. Seres Therapeutics has a 52 week low of $8.85 and a 52 week high of $15.09. The stock’s market cap is $547.69 million.
Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.10. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The business had revenue of $3 million during the quarter, compared to the consensus estimate of $3 million. During the same quarter in the prior year, the firm posted ($0.70) EPS. The company’s revenue for the quarter was up .0% compared to the same quarter last year. On average, equities analysts anticipate that Seres Therapeutics will post ($2.48) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “HC Wainwright Reaffirms “Buy” Rating for Seres Therapeutics, Inc. (MCRB)” was first posted by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/08/04/hc-wainwright-raises-seres-therapeutics-inc-mcrb-price-target-to-19-00.html.
Several hedge funds and other institutional investors have recently bought and sold shares of MCRB. Alps Advisors Inc. raised its position in Seres Therapeutics by 5.0% in the second quarter. Alps Advisors Inc. now owns 36,457 shares of the biotechnology company’s stock valued at $412,000 after buying an additional 1,739 shares during the period. State of Wisconsin Investment Board purchased a new position in Seres Therapeutics during the second quarter valued at approximately $169,000. Rhumbline Advisers raised its position in Seres Therapeutics by 14.8% in the second quarter. Rhumbline Advisers now owns 22,472 shares of the biotechnology company’s stock valued at $254,000 after buying an additional 2,890 shares during the period. DekaBank Deutsche Girozentrale purchased a new position in Seres Therapeutics during the second quarter valued at approximately $236,000. Finally, Schwab Charles Investment Management Inc. raised its position in Seres Therapeutics by 0.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 91,543 shares of the biotechnology company’s stock valued at $1,035,000 after buying an additional 494 shares during the period. Hedge funds and other institutional investors own 75.31% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.